ProCE Banner Activity

Menin Inhibition in the Treatment of MLL-Rearranged Acute Leukemias: A Promising New Strategy

Clinical Thought

Learn the latest on the emerging role of menin inhibition in MLL-rearranged acute leukemias.

Released: October 26, 2022

Expiration: October 25, 2023

Share

Faculty

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Syndax

Faculty Disclosure

Primary Author

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie/Genentech, Amgen, Astellas/Jazz, Bristol-Myers Squibb/Celgene/Kite, Daiichi Sankyo, Gilead Sciences, GlaxoSmithKline, Janssen, Kura Oncology, Mana Therapeutics, Novartis, Pfizer, PharmaEssentia, NuProbe, Rafael, Stemline, Takeda; fees for non-CME/CE services: Astellas/Jazz, Dava Oncology, Kura Oncology, Pfizer, Stemline.